Captopril in the management of patients after acute myocardial infarctions. A cost effectiveness analysis in Italy.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Pharmacological Research

• Publication date

  1998-05-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1006/PHRS.1998.0297PMID 9642029
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Quantitative Two-dimensional Echocardiographic Measurements Are Major Predictors of Adverse Cardiovascular Events After Acute Myocardial Infarction The Protective Effects of Captopril

  2005cited by this paper
• Modelling in economic evaluation: an unavoidable fact of life.

  1997cited by this paper
• Clinical and health economic benefit of calcium and vitamin D supplementation in the prevention of osteoporotic fractures

  1997cited by this paper
• The perspective of a pharmacoeconomic study: targeting for audiences.

  1997cited by this paper
• Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands.

  1996cited by this paper
• [Cost effectiveness of captopril after myocardial infarct; comment].

  1996cited by this paper
• The role of quantitative modelling in health care.

  1995cited by this paper
• Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.

  1995cited by this paper
• Cost-effectiveness of captopril therapy after myocardial infarction.

  1995cited by this paper
• A proposal for Italian guidelines in pharmacoeconomics The Mario Negri Institute Centre for Health Economics.

  1995cited by this paper
• Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial.

  1995cited by this paper
• [Cost-effectiveness analysis of captopril treatment after myocardial infarction].

  1994cited by this paper
• GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico.

  1994cited by this paper
• Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis.

  1994cited by this paper
• Cost-effectiveness of streptokinase for acute myocardial infarction: A combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction.

  1994cited by this paper
• Myocardial Infarction and Coronary Deaths in the World Health Organization MONICA Project: Registration Procedures, Event Rates, and Case‐Fatality Rates in 38 Populations From 21 Countries in Four Continents

  1994cited by this paper
• GISSI-3: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction

  1994cited by this paper
• Coronary heart disease case fatality in four countries. A community study. The Acute Myocardial Infarction Register Teams of Auckland, Augsburg, Bremen, FINMONICA, Newcastle, and Perth.

  1993cited by this paper
• Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

  1992cited by this paper
• Progressive ventricular remodeling in rat with myocardial infarction.

  1991cited by this paper
• Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications

  1990cited by this paper
• High doses of L-carnitine in acute myocardial infarction: metabolic and antiarrhythmic effects.

  1989cited by this paper
• Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes

  1988cited by this paper
• Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction.

  1987cited by this paper
• Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion.

  1986cited by this paper
• Risk stratification for 1 year survival based on characteristics identified in the early hours of acute myocardial infarction. The Western Washington Intracoronary Streptokinase Trial.

  1986cited by this paper
• Risk stratification and survival after myocardial infarction.

  1983cited by this paper
• Myocardial carnitine deficiency in acute myocardial infarction.

  1982cited by this paper
• Left Ventricular Diastolic Pressure‐Volume Relations in Rats with Healed Myocardial Infarction: Effects on Systolic Function

  1981cited by this paper
• Principles of Economic Appraisal in Health Care

  1981cited by this paper
• Effects of L-carnitine on tissue levels of acyl carnitine, acyl coenzyme A and high energy phosphate in ischemic dog hearts.

  1981cited by this paper
• Regional cardiac dilatation after acute myocardial infarction: recognition by two-dimensional echocardiography.

  1979cited by this paper
• Prognosis after initial myocardial infarction: the Framingham study.

  1979cited by this paper
• Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations.

  1979cited by this paper
• Changes in tissue levels of carnitine and other metabolites during myocardial ischemia and anoxia.

  1978cited by this paper
• Foundations of cost-effectiveness analysis for health and medical practices.

  1977cited by this paper

• About the Reliability of the Critical Review to Investigate the Generalizability of Economic Evaluations Conducted in Italy.

  2016cites this paper
• Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMILE-4

  2013cites this paper
• Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMILE-4

  2013cites this paper
• L’utilizzo di modelli decisionali per le valutazioni economiche dei farmaci in Italia: stato dell’arte e prospettive future

  2007cites this paper
• Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).

  2005cites this paper
• Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.

  2005cites this paper
• Direct Medical Costs Attributable to Acute Myocardial Infarction and Ischemic Stroke in Cohorts with Atherosclerotic Conditions

  2004cites this paper
• L-CARNITINE IN THE MANAGEMENT OF PATIENTS AFTER ACUTE MYOCARDIAL INFARCTION : A COST EFFECTIVENESS ANALYSIS IN ITALY

  1998cites this paper